<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Two_Unconventional_Some_Tips_On_Galunisertib</id>
		<title>Two Unconventional Some Tips On Galunisertib - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Two_Unconventional_Some_Tips_On_Galunisertib"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Two_Unconventional_Some_Tips_On_Galunisertib&amp;action=history"/>
		<updated>2026-05-05T21:47:48Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=Two_Unconventional_Some_Tips_On_Galunisertib&amp;diff=121800&amp;oldid=prev</id>
		<title>Curleregypt6: Створена сторінка: The normality of distribution of the quantitative data was [http://www.selleckchem.com/products/ly2157299.html Smad inhibitor] verified using the Kolmogorow�C...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Two_Unconventional_Some_Tips_On_Galunisertib&amp;diff=121800&amp;oldid=prev"/>
				<updated>2016-12-15T20:07:19Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: The normality of distribution of the quantitative data was [http://www.selleckchem.com/products/ly2157299.html Smad inhibitor] verified using the Kolmogorow�C...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;The normality of distribution of the quantitative data was [http://www.selleckchem.com/products/ly2157299.html Smad inhibitor] verified using the Kolmogorow�CSmirnow test. Between-group comparisons of quantitative variables were performed with the use of a Student's t-test (normally distributed data) or a Mann�CWhitney U-test (non-normally distributed data). For qualitative data a chi squared test was used, with Yate's correction where necessary. In the cases of p?[http://www.selleckchem.com/products/z-vad-fmk.html learn more] patients. After analyzing demographic, pharmacologic, and echocardiographic data, the patients with successful cardioversion differed only in the higher use of statins (68.8% vs. 42.1%, p?=?0.03). In a univariate analysis, only the use of statins was the significant predictor of EC success (OR?=?1.09, Cl?��?95% 1.001�C1.019, p?[http://en.wikipedia.org/wiki/RhoC RhoC] (31.2%, Group I). In 42 patients (68.8%, Group II), AF recurrences were registered. The characteristics of both groups are presented in Table 3?and?Table 4. In Group I, only mitral valve deceleration time (MVDT) (224.18?��?88.13 vs. 181.6?��?60.6 in Group II, p?=?0.04) and dispersion of TPLS (86.0?��?68.3 vs. 151.8?��?89.6, p?=?0.03) were significantly different. In a univariate analysis among the clinical, demographical, and echocardiographic parameters, only dTPLS was a significant predictor of SR maintenance at 6-month follow-up ( Table 5?and?Table 6). Drawing the ROC curve allowed us to determine that dTPLS below a cutoff point of 128?ms predicts SR maintenance at 6 months after EC with 57% sensitivity, 83% specificity, 66% accuracy, 87% positive predictive value, and 50% negative predictive value (AUC 0.66) (Fig. 2). In patients with persistent AF, we assessed factors predicting acute EC success and SR maintenance at 6 months. It is known that duration of stunning following cardioversion may take up to a few weeks.&lt;/div&gt;</summary>
		<author><name>Curleregypt6</name></author>	</entry>

	</feed>